The CF Foundation supports a wide range of innovative research programs to discover and develop new and effective CF therapies.
We facilitate the development of promising drugs and therapies for people with CF. Clinical trials that test these are a major part of CF research, and they take place at Foundation-accredited care centers all over the United States. In addition, the drug development pipeline enables you to track the progress of these potential therapies, whether or not you're part of the clinical trial.
We're attacking CF from every angle. Explore the interactive pipeline to learn more about CF drugs in development or already in use by patients.
Help blaze a trail to better treatments and a cure for cystic fibrosis. As a clinical trial volunteer, you are paving the way for new treatments. Learn more and search for trials that may be right for you and your family.
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for CF, and supports a broad range of research initiatives to tackle the disease from all angles.
Research by dedicated scientists and clinicians from a wide range of disciplines is expanding our knowledge of cystic fibrosis, translating discoveries and insights into vital new treatments and clinical care practices for people living with CF.
The CF Foundation is the world's leader in the fight against CF. Our scientific portfolio reflects our drive to provide effective treatments and -- one day -- a cure to EVERY individual with this disease.
The journey to end cystic fibrosis isn't a straight line. It is an evolving map with many paths and unique challenges. It requires an ambitious research agenda to accelerate treatments and drug development for the underlying cause of the disease and ultimately deliver a cure.
We have committed at least $100 million from 2019-2023 to a comprehensive effort to improve the detection, diagnosis, treatment, and outcomes of CF-related infections. Since the launch of the Infection Research Initiative in 2018, we have awarded over $58 million to infection research.